Neurocine Biosciences won FDA approval on Tuesday for a new formulation that may help Ingrezza go down in a more delightful ...

GSK’s vac­cines port­fo­lio is front and cen­ter as it kicks off 2024. The UK phar­ma made £7.36 bil­lion ($9.18 bil­lion) in ...

Pfiz­er trimmed a hand­ful of pro­grams from its pipeline Wednes­day morn­ing as part of its first-quar­ter earn­ings up­date ...

Real Chemistry plans to harness the “Wild West” of GLP-1 social media and reams of competitive data in the drug category with ...

Novartis is looking to build on its radiopharma research machinery. The maker of Lutathera and Pluvicto has expanded its ...

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) Pic­tion Health, which ...

UnitedHealth Group's CEO Andrew Witty is set to testify before lawmakers on Wednesday to explain how the company handled ...

Moderna is inviting LinkedIn and Instagram scrollers to take a break with its scientists in a Coffee Break Science series that started this week. The short videos lead off with infectious disease ...

Enlaza Therapeutics raised $100 million to develop permanently binding antibody-drug conjugates for cancer with a goal of ...

As part of its quarterly cleaning, Eli Lilly removed a few trials from its pipeline, including late-stage studies of approved ...

Pacific Biosciences is letting go of 190 employees, according to the company, as part of cost-cutting measures after ...

Rising demand for Eli Lilly’s diabetes and obesity drugs have buoyed first-quarter sales to $8.77 billion, pushing the ...